Quality and Regulatory Sourcebook eBook March 2023
Read the article:
Evolution of Analytical Procedure Validation Concepts: Part I
Read Part II:
Evolution of Analytical Procedure Validation Concenpts: Part II
Read the eBook:
Evolution of Analytical Procedure Validation Concepts: Part I
Publication
Article
BioPharm InternationalBioPharm International Quality and Regulatory Sourcebook 2023
Volume 2023 eBook
Issue 1
Pages: 14–21
This article provides an overview of validation concept principles evolution to a life cycle risk-based approach with focus on compendial perspectives.
sewcream - Stock.adobe.com
In recent years, regulatory agencies have placed an increased emphasis on pharmaceutical process understanding through adoption of quality-by-design (QbD) principles by launching a series of initiatives to encourage the pharmaceutical industry to adopt QbD in the manufacturing process. A key component of this transformation is the evolution of validation concepts to a life cycle risk-based approach driven by analytical quality by design (AQbD) principles. Different pharmacopoeias have been developing compendial approaches to support the implementation of analytical procedure life cycle (APLC) risk-based approach. Additionally, the International Council for Harmonisation (ICH) released in March 2022 two draft guidelines for public consultation which outline QbD principles: ICH Q14 (procedure development) (1), and the ICH Q2(R2) (procedure validation) (2). In a series of two articles, the authors will provide an overview of the validation concept principles evolution with a focus on compendial perspectives (Part I) and draw a parallel between ICH Q14 and Q2(R2) and United States Pharmacopeia (USP) General Chapter <1220> and the ISO/IEC 17025:2017 (Part II).
Read the article in BioPharm International’s Quality and Regulatory Sourcebook March 2023
About the authors
Amanda Guiraldelli is scientific affairs manager at the United States Pharmacopeia.
Jane Weitzel is an independent consultant and chair of the US Pharmacopeia Expert Committee on Measurement and Data Quality.
Article details
BioPharm International
eBook: Quality and Regulatory Sourcebook 2023
March 2023
Pages: 14–21
Citation
When referring to this article, please cite it as Guiraldelli, A. and Weitzel, J. Evolution of Analytical Procedure Validation Concepts: Part I. BioPharm International Quality and Regulatory Sourcebook 2023. March 2023.
Articles in this issue
Mitigating Human Error and Supporting Compliance with Smart Technology
Phase-appropriate Analytical Methodology
Evolution of Analytical Procedure Validation Concepts: Part II
Pharmacovigilance Automation
Evolution of Analytical Procedure Validation Concepts: Part I
Points to Consider for Knowledge Management Acceleration
Recent Videos
Related Content
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025Article
The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Article
Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
